budesonide inhalation suspension / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
budesonide inhalation suspension / Generic mfg.
2006-004035-30: A Randomised, Single Dose Exposure Study to Assess the Safety, Tolerability and Pharmacokinetics of Investigational Captisol-Enabled® Budesonide InhalationSolution (CBIS) Delivered via eFlow® Nebuliser and Conventional BudesonideInhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® JetNebuliser in Children with Asthma

Ongoing
2
18
Europe
Captisol-Enabled Budesonide, Pulmicort 250 Respules, CBIS, Pulmicort 250 Respules, Pulmicort 250 Respules
Verus Pharmaceuticals Inc
Asthma
 
 
2007-001968-78: A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 (Theophylline Solution for Inhalation) on Markers of Pulmonary Inflammation in Subjects with Moderate to Severe COPD

Ongoing
2
65
Europe
ADC4022, Pulmicort Respules, ADC4022, Budesonide, Pulmicort Respules 1 mg Nebuliser Suspension, Pulmicort Respules 1 mg Nebuliser Suspension
Argenta Discovery Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
 
 
BOREAS, NCT04933383: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics

Completed
1/2
23
Europe
AQ001S 0.125 mg/ml, budesonide inhalation solution 0.125 mg/ml, Budesonide 0.125 mg/ml inhalation suspension, Budesonide inhalation suspension 0.125 mg/ml
Aquilon Pharmaceuticals S.A.
Asthma
12/22
01/23

Download Options